

6 March 2023

Treatment of Non-small cell lung cancer (NSCLC)

Information as available from RISOH (regional information system oncology & haematology)

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib : <5
- Alectinib : <5
- Amivantamab : <5
- Atezolizumab monotherapy : <5
- Atezolizumab with chemotherapy : <5
- Brigatinib : <5
- Ceritinib : <5
- Crizotinib : <5
- Dacomitinib : <5
- Dabrafenib with Trametinib : <5
- Durvalumab : <5
- Erlotinib : <5
- Gefitinib : <5
- Lorlatinib : <5
- Mobocertinib : <5
- Nintedanib with Docetaxel : <5
- Nivolumab : <5
- Osimertinib : 12
- Pembrolizumab monotherapy : 11
- Pembrolizumab with chemotherapy : 8
- Pemetrexed with Carboplatin/Cisplatin : <5
- Pralsetinib : <5
- Selpercatinib : <5
- Sotorasib : <5
- Tepotinib : <5
- Vinorelbine with Carboplatin/Cisplatin : 15
- Any other active systemic anti-cancer therapy (SACT) Gem/Carbo : <5
- Palliative care only : Not available via RISOH query field

6 March 2023

Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

- Atezolizumab monotherapy : <5
- Atezolizumab with chemotherapy : <5
- Durvalumab : <5
- Nivolumab : <5
- Osimertinib : <5
- Pembrolizumab (Keytruda) Mono : <5
- Pembrolizumab (Keytruda) with Chemotherapy : <5
- Tepotinib : <5
- Other active systemic anti-cancer therapy (SACT) Carbo/Cisplatin + Vinorelbine : 6 & Gemcitabine & carboplatin : <5
- Palliative care only : Not available via RISOH query field

Please note:

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.